


## DNDI-8219

Cat. No.:	HY-124623
CAS No.:	2222660-40-2
Molecular Formula:	C <sub>13</sub> H <sub>10</sub> F <sub>3</sub> N <sub>3</sub> O <sub>5</sub>
Molecular Weight:	345.23
Target:	Parasite
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	DNDI-8219 (compound 58) is a potent selective and orally active trypanocidal agent, possessing inhibitory activity against <i>Trypanosoma cruzi</i> (T. cruzi) with an IC <sub>50</sub> of 0.4 μM. DNDI-8219 has low cytotoxicity (L6 cells IC <sub>50</sub> > 100 μM). DNDI-8219 can effectively cure chronic T. cruzi infection and markedly reduce parasite burdens in mouse model. DNDI-8219 has good solubility, metabolic stability and safety.								
<b>IC<sub>50</sub> &amp; Target</b>	Trypanosoma								
<b>In Vivo</b>	<p>DNDI-8219 (50 or 100 mg/kg; PO; once daily for five days) completely cures chronic infection, as well as markedly reduces parasite burdens in mice<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Female BALB/c mice (infected with T. cruzi; n=5)<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>50 or 100 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>PO; once daily for five days</td> </tr> <tr> <td>Result:</td> <td>Completely cured one of five mice in a chronic infection mouse model, as well as markedly reduced parasite burdens in two other mice.</td> </tr> </table>	Animal Model:	Female BALB/c mice (infected with T. cruzi; n=5) <sup>[1]</sup>	Dosage:	50 or 100 mg/kg	Administration:	PO; once daily for five days	Result:	Completely cured one of five mice in a chronic infection mouse model, as well as markedly reduced parasite burdens in two other mice.
Animal Model:	Female BALB/c mice (infected with T. cruzi; n=5) <sup>[1]</sup>								
Dosage:	50 or 100 mg/kg								
Administration:	PO; once daily for five days								
Result:	Completely cured one of five mice in a chronic infection mouse model, as well as markedly reduced parasite burdens in two other mice.								

### REFERENCES

[1]. Thompson AM, et al. Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy. *Eur J Med Chem.* 2020;207:112849.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA